Video

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

MK-6482 targets the transcription factor HIF-2, which is said to be very difficult to target and was thought to be undruggable, Choueiri explains. HIF-2 is an important target in clear cell RCC, he adds, because clear cell RCC is defined by VHL alteration that leads to upregulation in HIF-2. Earlier data have demonstrated that small molecules can enter one of the HIF-2 pockets and inhibit the heterodimerization; these data led to the development of molecules, such as MK-6482.

In this phase I/II study, investigators evaluated 55 previously treated patients with clear cell RCC; the median lines of prior therapy was 3. Results showed that the objective response rate with MK-6482 was 24%, with 69% of patients experiencing tumor shrinkage. Moreover, the median progression-free survival was 11 months, and responses were also observed in International Metastatic RCC Database Consortium poor-risk patients, Choueiri concludes.

<<< View more from the 2020 Genitourinary Cancers Symposium

Related Videos
Arya Mariam Roy, MBBS
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center